𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comparative electrophysiological study of response to botulinum toxin type B in Japanese and Caucasians

✍ Scribed by Kimiyoshi Arimura; Yumiko Arimura; Yoshiharu Takata; Tomonori Nakamura; Ryuji Kaji


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
136 KB
Volume
23
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Ethnic differences in the muscle‐relaxing effect of botulinum toxin type B (BTX‐B) were examined by means of electrophysiological measurements in Japanese and Caucasian volunteers. This was a randomized, single‐blinded, single‐center study of 24 Japanese and 24 Caucasian healthy adult male subjects in Japan. BTX‐B (20 U, 100 U, or 500 U/0.2 mL) or placebo was administered to the extensor digitorum brevis (EDB) muscle in the left lower limb as a single dose (in each dose group, 6 subjects received the test drug and two received placebo). The inhibitory effect of BTX‐B on the M wave amplitude of EDB muscle generated by stimulation of the deep peroneal nerve was measured frequently during 2 weeks after administration, and then at weeks 4 (day 28) and 12 (day 84). The inhibitory effect of BTX‐B on the M wave amplitude of EDB muscle was dose‐dependent in both Japanese and Caucasian subjects, and the dose‐response curves were similar. These findings demonstrate that the muscle‐relaxing effect of BTX‐B in Japanese subjects is electrophysiologically similar to that in Caucasians. © 2007 Movement Disorder Society


📜 SIMILAR VOLUMES


BotB (botulinum Toxin type B): Evaluatio
✍ Dr. Daniel D. Truong; Paul A. Cullis; Christopher F. O'Brien; Martin Koller; Tim 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 314 KB

## Abstract Botulinum toxin (BTX) injection is considered the treatment of choice for patients with cervical dystonia (torticollis). We conducted a pilot, open‐label, dose‐escalation study with BTX type B in 12 patients who no longer responded clinically to injections with BTX type A. At the doses

Efficacy and safety of repeated doses of
✍ Stewart A. Factor; Eric S. Molho; Sharon Evans; Paul J. Feustel 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

## Abstract Efficacy of botulinum toxin type B (BoNT B) for the treatment of type A‐resistant (AR) and non‐A‐resistant (NAR) cervical dystonia (CD) has been demonstrated in several single injection studies. There is little data available on long‐term therapy with repeated injection sessions and it

Double-blind, placebo-controlled study t
✍ Francesca Mancini; Roberta Zangaglia; Silvano Cristina; Maria Grazia Sommaruga; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 2 views

## Abstract Drooling is a frequent symptom in Parkinson's disease (PD), occurring in almost 75% of all patients. Although it is now well known that drooling in PD is the result of swallowing difficulties rather than excessive saliva production, few treatments have been developed to reduce it. Clini

Secondary non-response due to antibody f
✍ Steffen Berweck; A Sebastian Schroeder; Seung-Hee Lee; Hans Bigalke; Florian Hei 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

Botulinum toxin (BTX) offers a new treatment option to reduce drooling in adults and children. Antibody formation against BTX is known to be one reason for clinical secondary non‐response to this treatment. This is a case report on the development of secondary non‐response to BTX type B (BTX‐B) in a

DYSBOT: A single-blind, randomized paral
✍ Dr. Cristina Sampaio; Joaquim J. Ferreira; Fernanda Simões; Maria J. Rosas; Mari 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 561 KB

## Background: Elston and russell discovered a difference in the biological potency of the english formulation of botulinum toxin type a or btx-a (dysport) and the american formulation (botox). potency of both is expressed in ld50 mouse units, but because of assay differences, these units are not e